Learn how the latest BTK and BCL-2 inhibitors influence first-line treatment choices in chronic lymphocytic leukemia (CLL). This activity compares continuous versus fixed-duration dosing and reviews real-world and trial evidence to support personalizing patient care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
IPCE CreditsUp to 0.5 creditsAAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits
MOC types
ABIM — Medical KnowledgeUp to 0.5 points
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Pricing
100% of listed courses are free
56 of 56 courses listed here are free.
Collected from the provider’s public pages
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedDec 10, 2025
-
Last day to claim creditFeb 28, 2027 5 months left
-
Stitched Health, Inc. +1 Advancing Confident, Evidence- and Guideline-Aligned Treatment Selection in Chronic Lymphocytic Leukemia
-
Efficient CME, CME Outfitters, LLC Evidence in Action: Using Expert Insights and Practice Patterns to Guide Optimal Treatment of Chronic Lymphocytic Leukemia
-
HealthTree Foundation for Chronic Lymphocytic Leukemia +1 FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment
